1 / 20

Association of C hronic K idney D isease with Allopurinol Use in Gout Treatment

Explore the association between allopurinol use in gout patients and the risk of developing chronic kidney disease stage 3 or higher. Findings suggest a potential beneficial effect of allopurinol in reducing CKD risk.

haamid
Download Presentation

Association of C hronic K idney D isease with Allopurinol Use in Gout Treatment

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Association of Chronic Kidney Diseasewith Allopurinol Use in Gout Treatment Ana Beatriz Vargas-Santos, MD; Christine E. Peloquin, MPH; Yuqing Zhang, DSc; TuhinaNeogi, MD, PhD JAMA Internal Medicine2018;178(11):1526-1533.

  2. Research Question • What is the association of allopurinol use in patients with gout with the risk of developing chronic kidney disease stage 3 or higher?

  3. 痛風的成因

  4. Importance • Clinicians are often cautious about use of allopurinol in patients with gout when renal function declines • there is no evidence that allopurinol is nephrotoxic

  5. Objective   • To assess the association of allopurinol use in gout with the risk of developing chronic kidney disease stage 3 or higher.

  6. Study Design • time-stratified PSM cohort study • data sources: UK GPs (The Health Improvement Network)

  7. Study Design • Included • 18-89 years, new dx. gout • 2000/1/1−2014/12/31 • @ last 1 year • Excluded • prior CKD stage 3↑ (& ESRD) • prior urate-lowering therapy • prior other conditions • due to time-stratified PSM cohort study design

  8. Outcome definition

  9. Statistical analysis • Cox proportional hazards model • Kaplan-Meier curves • Sensitivity analysis • censoring at exposure status change • included all allopurinol initiators (dose <300 mg/d)

  10. Results

  11. Results

  12. Results

  13. Results

  14. Results

  15. Discussion • previous studies about allopurinol … • no significant association with renal function • but not directly applicable to gout patients • gout studies • small sample sizeor not target for gout (hypertensive) • same founding with other studies  potential beneficial

  16. Strengths & Limitations

  17. Conclusion • Allopurinolwas associated with 13%reduction the riskof developingCKD stage 3+

  18. Comments

  19. Thanks for your attentionAny comments?

More Related